Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

2012 ◽  
Vol 56 (1) ◽  
pp. 176-183 ◽  
Author(s):  
Huanjie Shao ◽  
Chun Gao ◽  
Haikuo Tang ◽  
Hao Zhang ◽  
Lewis R. Roberts ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Dual Targeting ◽  
Deacetylase Inhibitor

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo

2006 ◽  
Vol 5 (7) ◽  
pp. 1693-1701 ◽  
Author(s):  
Z. Alexander Cao ◽  
Kathryn E. Bass ◽  
Sriram Balasubramanian ◽  
Liang Liu ◽  
Brian Schultz ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Broad Spectrum ◽  
Histone Deacetylase Inhibitor ◽  
Antiangiogenic Activity ◽  
Deacetylase Inhibitor

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

2002 ◽  
Vol 64 (7) ◽  
pp. 1079-1090 ◽  
Author(s):  
Yuka Sasakawa ◽  
Yoshinori Naoe ◽  
Takeshi Inoue ◽  
Tatsuya Sasakawa ◽  
Masahiko Matsuo ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Human Lymphoma

scholarly journals Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53

2020 ◽  
Vol 16 (16) ◽  
pp. 3184-3199
Author(s):  
Batsaikhan Buyandelger ◽  
Eli E Bar ◽  
Kuo-Sheng Hung ◽  
Ruei-Ming Chen ◽  
Yung-Hsiao Chiang ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Glioma Growth

scholarly journals Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

Leukemia ◽  
2004 ◽  
Vol 18 (12) ◽  
pp. 1951-1963 ◽  
Author(s):  
E Weisberg ◽  
L Catley ◽  
J Kujawa ◽  
P Atadja ◽  
S Remiszewski ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Significant Activity ◽  
Deacetylase Inhibitor

Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo

2015 ◽  
Vol 764 ◽  
pp. 508-519 ◽  
Author(s):  
Saranya Nidhyanandan ◽  
Thippeswamy S. Boreddy ◽  
Kothapalli B. Chandrasekhar ◽  
Neetinkumar D. Reddy ◽  
Nagaraj M. Kulkarni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Anticancer Activity ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Human Breast Cancer ◽  
Phosphodiesterase Inhibitor ◽  
Human Breast ◽  
Deacetylase Inhibitor

scholarly journals MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

2008 ◽  
Vol 7 (4) ◽  
pp. 759-768 ◽  
Author(s):  
Marielle Fournel ◽  
Claire Bonfils ◽  
Yu Hou ◽  
Pu Theresa Yan ◽  
Marie-Claude Trachy-Bourget ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Histone Deacetylase ◽  
Broad Spectrum ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor

scholarly journals Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But

2004 ◽  
Vol 10 (14) ◽  
pp. 4822-4830 ◽  
Author(s):  
Danila Coradini ◽  
Sonia Zorzet ◽  
Raffaella Rossin ◽  
Ignazio Scarlata ◽  
Cinzia Pellizzaro ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Hepatic Metastases ◽  
Hepatocellular Carcinomas ◽  
Deacetylase Inhibitor

scholarly journals Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies

Cancers ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 414 ◽  
Author(s):  
Radhia M’kacher ◽  
Monika Frenzel ◽  
Mustafa Al Jawhari ◽  
Steffen Junker ◽  
Corina Cuceu ◽  
...  
Keyword(s):  
Animal Model ◽  
Histone Deacetylase ◽  
High Frequency ◽  
Histone Deacetylase Inhibitor ◽  
Telomerase Activity ◽  
Nsg Mice ◽  
Deacetylase Inhibitor

To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.

Sign in / Sign up

Export Citation Format

Share Document